3 results
The primary objective of this study is to compare PFS with LY2875358 plus erlotinib therapy with erlotinibmonotherapy as first-line treatment in metastatic NSCLC patients with activating EGFR mutations who havedisease control after an 8-week lead-in…
Primary:• The primary objective of the study is to demonstrate the efficacy of vorasidenib based on radiographic progression-free survival (PFS) per blinded independent review committee (BIRC) compared with placebo in subjects with residual or…
The objective of this study is to evaluate the 12-month outcomes of stenting with the Supera Peripheral Stent System (Abbott Vascular) versus endarterectomy in symptomatic (Rutherford 2-4) atherosclerotic lesions in the common femoral artery (CFA) (…